Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural
Continue Reading Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy
Although the Corporate Transparency Act (the “CTA”) is no longer halted by nationwide preliminary injunctions, U.S. companies and their beneficial
Continue Reading CTA Update: Domestic Reporting Companies Exempt from Reporting to FinCEN
For the past few months, the beneficial ownership reporting obligations under the Corporate Transparency Act (the “CTA”) have fluctuated between
Continue Reading Corporate Transparency Act Requirements Are Back: March 21, 2025 Deadline Looms
Only days after lifting the nationwide preliminary injunction, the Fifth Circuit Court of Appeals vacated their decision to stay the
Continue Reading Latest Update: Corporate Transparency Act Halted Again
As an update to our posts on the ongoing attempts to block the Corporate Transparency Act, on December 23, 2024
Continue Reading Update: Corporate Transparency Act Reinstated by Appeals Court: January 1 Deadline Looms
The United States Patent and Trademark Office (USPTO) announced today the finalized fee increases taking effect on January 19, 2025.
Continue Reading USPTO Finalizes Fee Increases for 2025: What to Expect in the New Year and What to do Now
The Corporate Transparency Act (CTA) went into effect on January 1, 2024, and will impact millions of U.S. businesses by
Continue Reading The Corporate Transparency Act: What you Need to Know to Comply with the New Requirements
Heading into 2025, patent applicants should prepare for significant fee increases at the United States Patent and Trademark Office (USPTO).
Continue Reading USPTO Fees Are Rising Drastically in 2025: What to Do Now to Save Thousands of Dollars
BASE Air is a company at the leading edge of safety in the heavy vehicle industry. Founded in 2005 by
Continue Reading Client Spotlight: BASE Air Management
In a long-awaited milestone in the gene therapy space, the Food and Drug Administration (FDA) approved two gene therapies to
Continue Reading Gene Therapy Approvals Gain Steam in 2023: FDA Approves First Gene Therapies for Sickle Cell Disease